$144.60
-7.88-5.17%
In chiusura: Nov 13, 4:00 PM EST
$144.01
-8.47-5.55%
Pre-mercato: 4:09 AM EST
The average analyst price target for Palvella Therapeutics is $176.15, 22.3% above the current price. Of 18 analysts, 18 rate it Buy. Targets range from $38 to $250. The latest change came on Nov 16, 2026, when Leerink Partners initiated coverage of Palvella Therapeutics with an Outperform rating and a $228 price target.
Price Target Range — 9 Quarters
Analyst Consensus — 18 Analysts
Rating Trend — Last 9 Months
